Kohlberg Kravis Roberts & Co’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio OYST Stock Details OYST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,039,622	Closed	-$11.6M	–	125
2022 Q4	$11.6M	Hold	1,039,622	–	–	0.39%	28
2022 Q3	$5.84M	Hold	1,039,622	–	–	0.12%	41
2022 Q2	$4.5M	Hold	1,039,622	–	–	0.06%	59
2022 Q1	$12.1M	Hold	1,039,622	–	–	0.11%	31
2021 Q4	$19M	Hold	1,039,622	–	–	0.1%	27
2021 Q3	$12.3M	Hold	1,039,622	–	–	0.06%	34
2021 Q2	$17.9M	Hold	1,039,622	–	–	0.07%	44
2021 Q1	$19M	Hold	1,039,622	–	–	0.1%	33
2020 Q4	$19.6M	Hold	1,039,622	–	–	0.1%	35
2020 Q3	$21.9M	Hold	1,039,622	–	–	0.13%	36
2020 Q2	$30M	Hold	1,039,622	–	–	0.18%	31
2020 Q1	$36.4M	Hold	1,039,622	–	–	0.23%	16
2019 Q4	$25.4M	Buy	+1,039,622	New	+$18.2M	0.12%	25

Other funds holding OYST

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's OYST Position: Q1 2023 in Review

Kohlberg Kravis Roberts & Co sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q1 2023, closing a stake of 1,039,622 shares — an estimated $11.6M sold.

Kohlberg Kravis Roberts & Co first reported a position in OYST in Q4 2019 and held it in 13 quarters. The position peaked at $36.4M in Q1 2020. 1 fund tracked by Wall St. Rank holds OYST as of Q1 2023.

Kohlberg Kravis Roberts & Co reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Kohlberg Kravis Roberts & Co sold 1,039,622 Oyster Point Pharma, Inc. Common Stock shares in Q1 2023, an estimated $11.6M.
Kohlberg Kravis Roberts & Co first reported a position in Oyster Point Pharma, Inc. Common Stock in Q4 2019 and held it in 13 quarters.
Kohlberg Kravis Roberts & Co's Oyster Point Pharma, Inc. Common Stock position peaked at $36.4M in Q1 2020.
1 fund tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q1 2023.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q1 2023, filed 15 May 2023.